Skip to main content
. Author manuscript; available in PMC: 2014 Sep 2.
Published in final edited form as: Leuk Lymphoma. 2014 Feb 4;55(9):1980–1992. doi: 10.3109/10428194.2013.855307

Table I.

Apoptosis pathway–targeting drugs in clinical trials.

Approach/Drug Other names Target Type Clinical Trial
Status
Company
Targeting Antiapoptotic BCL-2 Proteins
Oblimersen sodium G3139, Genasense, Augmerosen BCL-2 Antisense oligonucleotide Phase 3 Genta Incorporated
Obatoclax mesylate GX15-070 BCL-2, BCL-XL, BCL-w and MCL-1 Small-molecule inhibitor Phase 1/2 Gemin X/Teva Pharmaceutical Industries
AT-101 (−)-gossypol BCL-2, BCL-XL and MCL-1 Small-molecule inhibitor Phase 2 Ascenta Therapeutics
Navitoclax ABT-263 BCL-XL, BCL-2 and BCL-w Small-molecule inhibitor Phase 2 AbbVie and Genentech
GDC-0199 ABT-199 BCL-2 Small-molecule inhibitor Phase 1 AbbVie and Genentech
Targeting IAPs
AEG35156 GEM640 XIAP Antisense oligonucleotide Phase 1/2 Aegera Therapeutics
YM155 survivin Small-molecule antagonist Phase 2 Astellas Pharma
AT-406 Debio 1143 XIAP, cIAP1 and cIAP2 SMAC mimetic Phase 1 Ascenta Therapeutics and Debiopharm S.A.
TL32711 Birinapant cIAP1 SMAC mimetic Phase 1/2 TetraLogic Pharma
GDC-0917 IAPs SMAC mimetic Phase 1 Genentech
LCL161 IAPs SMAC mimetic Phase 1/2 Novartis
AEG40826-2HCl HGS1029 IAPs SMAC mimetic Phase 1 Aegera Therapeuics and GlaxoSmithKline/Human Genome Science?
LY2181308 Gataparsen survivin Antisense oligonucleotide Phase 2 Eli Lilly and Company
Targeting Death Receptors
rhApo2L/TRAIL Dulanermin DR4, DR5 Soluble ligand Phase 2 Genentech and Amgen
Mapatumumab HGS-ETR1, TRM-1 DR4 Monoclonal antibody Phase 2 GlaxoSmithKline/Human Genome Sciences
Lexatumumab HGS-ETR2 DR5 Monoclonal antibody Phase 1 GlaxoSmithKline/Human Genome Sciences
Drozitumab PRO95780, Apomab DR5 Monoclonal antibody Phase 2 Genentech
AMG655 Conatumumab DR5 Monoclonal antibody Phase 2 Amgen
CS-1008 Tigatuzumab DR5 Monoclonal antibody Phase 2 Daiichi
LBY-135 DR5 Monoclonal antibody Novartis
TAS266 DR5 Nanobody Phase 1 Novartis

IAP, inhibitor of apoptosis proteins; SMAC, second mitochondria-derived activator of caspase